Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PID
MCID: PLV003
MIFTS: 55

Pelvic Inflammatory Disease (PID)

Categories: Nephrological diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pelvic Inflammatory Disease

About this section

MalaCards integrated aliases for Pelvic Inflammatory Disease:

Name: Pelvic Inflammatory Disease 12 74 54 42 3 43 15 17 71
Pid 12 3

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1003
ICD9CM 34 614.9
MeSH 43 D000292
NCIt 49 C3889
SNOMED-CT 67 198130006
ICD10 32 N73.9
UMLS 71 C0242172
Sources

Summaries for Pelvic Inflammatory Disease

About this section
MedlinePlus : 42 Pelvic inflammatory disease (PID) is an infection and inflammation of the uterus, ovaries, and other female reproductive organs. It causes scarring in these organs. This can lead to infertility, ectopic pregnancy, pelvic pain, abscesses, and other serious problems. PID is the most common preventable cause of infertility in the United States. Gonorrhea and chlamydia, two sexually transmitted diseases, are the most common causes of PID. Other bacteria can also cause it. You are at greater risk if you Are sexually active and younger than 25 Have more than one sex partner Douche Some women have no symptoms. Others have pain in the lower abdomen, fever, smelly vaginal discharge, irregular bleeding, and pain during intercourse or urination. Doctors diagnose PID with a physical exam, lab tests, and imaging tests. Antibiotics can cure PID. Early treatment is important. Waiting too long increases the risk of infertility.

MalaCards based summary : Pelvic Inflammatory Disease, also known as pid, is related to endometritis and salpingitis, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Pelvic Inflammatory Disease is HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Akt Signaling. The drugs Aztreonam and Moxifloxacin have been mentioned in the context of this disorder. Affiliated tissues include testes, uterus and ovary, and related phenotypes are immune system and cardiovascular system

Disease Ontology : 12 A female reproductive system disease that is characterized by an infection of the female reproductive organs.

CDC : 3 Untreated sexually transmitted diseases (STDs) can cause pelvic inflammatory disease (PID), a serious condition, in women. 1 in 8 women with a history of PID experience difficulties getting pregnant. You can prevent PID if you know how to protect yourself.

Wikipedia : 74 Pelvic inflammatory disease, also known as pelvic inflammatory disorder (PID), is an infection of the... more...

Sources

Related Diseases for Pelvic Inflammatory Disease

About this section

Diseases related to Pelvic Inflammatory Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 560, show less)
# Related Disease Score Top Affiliating Genes
1 endometritis 33.2 TLR6 TLR4 TLR2 TLR1
2 salpingitis 33.0 TLR2 HSPD1 CRP CD40LG
3 peritonitis 32.7 TLR4 TLR2 MPO IFNG CRP CCL2
4 chlamydia 32.7 TLR4 TLR2 IFNG HSPD1 CRP CD40LG
5 cervicitis 31.3 TLR4 TLR2 IL2 HSPD1
6 syphilis 31.2 IFNG CRP CD40LG
7 appendicitis 30.8 TLR4 MPO MMP9 IL2 IFNG CRP
8 agammaglobulinemia, x-linked 30.8 IL2 CXCL12 CD40LG
9 urethritis 30.8 TLR4 TLR2 HSPD1 CRP CD40LG
10 common variable immunodeficiency 30.7 TLR2 MPO IL2 IFNG CD40LG
11 mastoiditis 30.7 MPO CRP CD40LG
12 irritable bowel syndrome 30.6 TLR4 TLR2 CRP
13 secondary progressive multiple sclerosis 30.6 MMP9 IFNG CD40LG CCL2
14 ileus 30.5 IFNG CRP CCL2
15 anogenital venereal wart 30.5 TLR6 TLR4 TLR2 TLR1 IL2
16 miliary tuberculosis 30.5 IFNG CRP CD40LG
17 salmonellosis 30.5 TLR6 TLR4 TLR2 TLR1 IFNG
18 immune deficiency disease 30.5 TLR2 IL2 IL13 IFNG CXCL12 CD40LG
19 exanthem 30.5 MPO IL2 IFNG CRP CD40LG
20 hyper ige syndrome 30.4 TLR4 TLR2 MMP9 IL13 IFNG
21 candidiasis 30.4 TLR4 TLR2 IL2 IFNG CD40LG
22 vulvovaginal candidiasis 30.4 TLR2 LCN2 IL2
23 dysentery 30.4 TLR4 TLR2 CRP CD40LG
24 cystitis 30.4 TLR4 IL2 CRP CDH1 CCL2
25 toxic shock syndrome 30.4 TLR4 TLR2 IL2 IFNG HSPD1 CRP
26 familial mediterranean fever 30.3 TLR4 TLR2 CRP
27 nocardiosis 30.3 IFNG HSPD1 CRP
28 adenomyosis 30.3 MMP9 MMP2 CDH1
29 gastroenteritis 30.3 MMP9 IFNG CRP CDH1
30 proctitis 30.3 MPO LCN2 CRP
31 pneumothorax 30.3 MMP9 MMP2 CRP
32 acquired immunodeficiency syndrome 30.3 IL2 IFNG CRP CD40LG
33 diarrhea 30.2 TLR4 MPO IL2 IL13 IFNG CDH1
34 pancytopenia 30.2 MPO IFNG CRP CD40LG
35 extrapulmonary tuberculosis 30.2 TLR2 TIRAP IFNG CRP CCL2
36 keratoconjunctivitis 30.2 MMP9 IL2 IL13 IFNG CCL2
37 myocarditis 30.2 TLR4 IL2 IFNG CD40LG CCL2
38 hypereosinophilic syndrome 30.1 MPO IL2 IL13 IFNG
39 pyelonephritis 30.1 TLR4 LCN2 IFNG CRP CCL2
40 acute cystitis 30.1 TLR4 TLR2 TLR1 LCN2 CRP CD40LG
41 cervical cancer 30.1 TLR4 MMP9 MMP2 IL2 IFNG CXCL12
42 skin disease 30.0 TLR2 IL2 IL13 IFNG CRP CD40LG
43 autoimmune disease 30.0 MMP9 IL2 IL13 IFNG HSPD1 CRP
44 neutropenia 29.9 TLR4 MPO IL2 IFNG CRP CD40LG
45 conjunctivitis 29.9 MPO MMP9 IL2 IL13 IFNG CCL2
46 body mass index quantitative trait locus 11 29.8 TLR6 TLR4 TLR2 TLR1 LCN2 CRP
47 brucellosis 29.8 TLR4 MPO IL2 IL13 IFNG CRP
48 bacterial infectious disease 29.7 TLR4 TLR2 TLR1 LCN2 IFNG HSPD1
49 lung disease 29.7 TLR4 TLR2 MPO MMP9 IL13 IFNG
50 chlamydia pneumonia 29.6 TLR6 TLR4 TLR2 TLR1 HSPD1 CRP
51 proteasome-associated autoinflammatory syndrome 1 29.5 TLR6 TLR4 TLR2 MPO MMP9 IL13
52 ovarian cancer 29.5 TLR4 MMP9 MMP2 LCN2 IL2 IFNG
53 meningitis 29.3 TLR4 TLR2 MMP9 IL2 IL13 IFNG
54 myocardial infarction 29.3 TLR4 TLR2 MPO MMP9 MMP2 LCN2
55 pneumonia 28.8 TLR6 TLR4 TLR2 MPO MMP9 IL2
56 colorectal cancer 28.6 TLR6 TLR4 TLR2 TLR1 MPO MMP9
57 fitz-hugh-curtis syndrome 11.8
58 benign multicystic peritoneal mesothelioma 11.2
59 pick disease of brain 11.2
60 heart valve disease 11.2
61 ectopic pregnancy 10.8
62 infertility 10.8
63 prolapse of lacrimal gland 10.7 MMP9 CD40LG
64 brawny scleritis 10.6 IFNG CD40LG
65 fungal keratitis 10.6 TLR4 TLR2 MMP9
66 bacterial vaginosis 10.6
67 prosthetic joint infection 10.6 TLR4 TLR2 CRP
68 neurosyphilis 10.6 TLR6 TLR2 TLR1
69 scalp dermatosis 10.6 TLR6 TLR2 TLR1
70 lateral ventricle meningioma 10.6 MMP9 CRP
71 extracranial arteriovenous malformation 10.6 MMP9 MMP2
72 aztreonam allergy 10.6 IL2 IL13
73 tuberculous meningitis 10.6 TLR2 MMP9 CCL2
74 focal myositis 10.6 MMP9 MMP2
75 cryptogenic organizing pneumonia 10.6 MMP9 CRP CD40LG
76 blood group, globoside system 10.6 TLR4 TLR2 CRP
77 autoimmune inner ear disease 10.6 MPO MMP9
78 autoimmune myocarditis 10.6 IFNG CCL2
79 systemic autoimmune disease 10.6 MMP9 CRP
80 rosacea 10.6 TLR2 MMP9 CRP
81 epididymis disease 10.6 TLR4 CRP CD40LG
82 gastrointestinal tuberculosis 10.6 IFNG CRP CD40LG
83 toxic pneumonitis 10.6 TLR6 TLR4
84 amebiasis 10.6 TLR4 TLR2 CD40LG
85 abdominal tuberculosis 10.6 IFNG CRP CD40LG
86 mikulicz disease 10.6 IL13 CRP CD40LG
87 fixed drug eruption 10.6 IL2 IFNG
88 neuritis 10.6 MMP9 IFNG CCL2
89 orchitis 10.6 IL2 CRP CD40LG
90 lung abscess 10.6 IFNG CRP CD40LG
91 boutonneuse fever 10.6 TLR4 IL2 CD40LG
92 sebaceous gland disease 10.6 TLR4 TLR2 CRP
93 lentigo maligna melanoma 10.6 MMP9 MMP2
94 filarial elephantiasis 10.6 TLR4 TLR2 IL13
95 erysipelas 10.6 IL2 CRP CD40LG
96 penile disease 10.6 TLR4 TLR2 IL2
97 uremic pruritus 10.6 IL2 CRP
98 oral tuberculosis 10.6 IL2 IFNG CRP
99 schnitzler syndrome 10.6 CRP CD40LG CCL2
100 japanese spotted fever 10.6 CRP CD40LG
101 angiostrongyliasis 10.6 MMP9 IL2 IL13
102 listeriosis 10.6 TLR4 TLR2 IL2
103 autoimmune disease of cardiovascular system 10.6 TLR4 CRP CD40LG
104 viral pneumonia 10.6 CRP CD40LG CCL2
105 bacterial sepsis 10.6 TLR4 TLR2 CRP
106 periapical granuloma 10.6 TLR2 IL2 CCL2
107 ocular toxoplasmosis 10.6 TLR1 CD40LG
108 orbital granuloma 10.6 MPO CRP
109 chorioretinitis 10.6 IL2 IFNG CD40LG
110 pyoderma 10.6 MMP9 CRP CD40LG
111 petrositis 10.6 IFNG CRP
112 purpura 10.6 IFNG CRP CD40LG
113 anus disease 10.6 TLR4 TLR2 IL2
114 acute transverse myelitis 10.5 MMP9 MMP2
115 pyuria 10.5 LCN2 CRP CD40LG
116 periapical periodontitis 10.5 TLR2 MMP9 MMP2
117 spondyloarthropathy 10.5 IL2 IFNG CCL2
118 african tick-bite fever 10.5 IL13 IFNG CD40LG
119 stevens-johnson syndrome/toxic epidermal necrolysis 10.5 IL2 IL13 IFNG
120 hereditary angioedema with normal c1inh 10.5 TLR4 TLR2 MPO
121 endometriosis 10.5
122 lichen disease 10.5 IL2 IFNG CD40LG
123 infective endocarditis 10.5 TLR6 TLR2 CRP
124 anuria 10.5 LCN2 CRP CD40LG
125 combat disorder 10.5 TLR6 TLR4 TLR2 TLR1
126 gingival disease 10.5 TLR4 TLR2 MMP9 CRP
127 mucocutaneous leishmaniasis 10.5 IL2 IL13 IFNG
128 aggressive periodontitis 10.5 TLR4 TLR2 CCL2
129 endometrial disease 10.5 TLR6 TLR4 TLR2 TLR1
130 chronic orbital inflammation 10.5 CRP CD40LG
131 suppurative otitis media 10.5 TLR4 TLR2 CRP CD40LG
132 tuberculous peritonitis 10.5 IFNG CRP
133 aseptic meningitis 10.5 IFNG CRP CD40LG
134 mononeuritis of upper limb and mononeuritis multiplex 10.5 MPO CRP CD40LG
135 mononeuritis multiplex 10.5 MPO CRP CD40LG
136 subacute bacterial endocarditis 10.5 MPO CRP CD40LG
137 ischemic colitis 10.5 MMP9 MMP2 CRP
138 allergic cutaneous vasculitis 10.5 MPO CD40LG
139 fallopian tube disease 10.5 TLR4 TLR2 CRP CD40LG
140 aortitis 10.5 MPO CRP CD40LG
141 legionnaire disease 10.5 TLR4 TLR2 CRP CD40LG
142 plague 10.5 TLR6 TLR4 TLR2 TLR1
143 spinal cord disease 10.5 IL2 CRP CD40LG
144 maxillary sinusitis 10.5 MPO CRP CD40LG
145 common cold 10.5 TLR4 TLR2 IL13
146 pericardial tuberculosis 10.5 IFNG CRP
147 vein disease 10.5 CRP CD40LG CCL2
148 autoimmune disease of skin and connective tissue 10.5 IL2 IFNG CD40LG
149 lipoid nephrosis 10.5 IL13 CD40LG CCL2
150 spastic entropion 10.5 MMP9 MMP2
151 hand, foot and mouth disease 10.5 TLR4 IL13 IFNG
152 vogt-koyanagi-harada disease 10.5 TLR4 TLR2 IFNG
153 plasmodium vivax malaria 10.5 IL2 IFNG CD40LG
154 bacterial pneumonia 10.5 TLR4 TLR2 CRP CD40LG
155 nonspecific interstitial pneumonia 10.5 IL13 IFNG CCL2
156 mononeuropathy 10.5 MPO CRP CD40LG
157 erythema multiforme 10.5 IL2 IL13 IFNG
158 melioidosis 10.5 TLR4 TLR2 TLR1 IFNG
159 autoimmune vasculitis 10.5 MPO IL2 CRP
160 proliferative glomerulonephritis 10.5 MPO IFNG CCL2
161 silicosis 10.5 TLR4 MMP9 CCL2
162 collagenous colitis 10.5 MPO MMP9 CD40LG
163 limited scleroderma 10.5 IL2 CRP CD40LG
164 autoimmune disease of endocrine system 10.5 IL2 IFNG CD40LG
165 rapidly progressive glomerulonephritis 10.5 MPO CRP CD40LG
166 crohn's colitis 10.5 IL2 IFNG CDH1
167 hypersensitivity vasculitis 10.5 MPO CRP CD40LG
168 cystic echinococcosis 10.5 TLR4 TLR2 IFNG CD40LG
169 echinococcosis 10.5 TLR4 TLR2 IFNG CD40LG
170 chronic meningitis 10.5 MMP9 IL13 CRP CD40LG
171 fasciitis 10.5 IL2 IFNG CRP
172 cytomegalovirus retinitis 10.5 IFNG CXCL12 CD40LG
173 posterior uveitis 10.5 IL2 IL13 IFNG
174 pericarditis 10.5 IFNG CRP CD40LG
175 vaginal discharge 10.5
176 henoch-schoenlein purpura 10.5 MPO CRP CD40LG
177 clonorchiasis 10.5 IL2 IFNG CTSB
178 hypersensitivity reaction type iii disease 10.5 MPO CRP CD40LG
179 tuberculoid leprosy 10.5 TLR2 IL2 IFNG CD40LG
180 chorioamnionitis 10.5 TLR4 MMP9 CRP CCL2
181 complex regional pain syndrome 10.5 IL2 IFNG CCL2
182 alcoholic hepatitis 10.5 TLR4 TLR2 CRP CCL2
183 acute pyelonephritis 10.5 LCN2 IFNG CRP
184 tropical spastic paraparesis 10.5 MMP9 IL2 IFNG
185 autoimmune uveitis 10.5 IL2 IFNG CCL2
186 aicardi-goutieres syndrome 10.5 TLR6 TLR4 TLR2 TLR1
187 carotid artery disease 10.5 MMP9 CRP CCL2
188 non-alcoholic steatohepatitis 10.5 TLR4 TLR2 MMP9 CCL2
189 scleritis 10.5 MMP9 IFNG CRP CCL2
190 aphthous stomatitis 10.5 TLR4 TLR2 IL2 IFNG
191 allergic conjunctivitis 10.5 IL2 IL13 IFNG
192 rheumatic fever 10.5 TLR2 IL2 IFNG CD40LG
193 eosinophilic meningitis 10.5 MMP9 IL2 IL13 CD40LG
194 lung giant cell carcinoma 10.5 MMP9 MMP2 CDH1
195 systolic heart failure 10.5 MMP9 MMP2 CRP
196 nasal cavity squamous cell carcinoma 10.5 MMP9 MMP2
197 chronic graft versus host disease 10.5 LCN2 IFNG
198 typhoid fever 10.5 TLR4 IFNG CRP CD40LG
199 atopic keratoconjunctivitis 10.5 IL2 IFNG
200 obstructive jaundice 10.5 TLR4 IL2 CRP CCL2
201 latent syphilis 10.5 IFNG CD40LG
202 viral meningitis 10.5 IFNG CRP CD40LG CCL2
203 ileitis 10.5 TLR4 TLR2 MPO
204 neuroretinitis 10.5 CRP CD40LG
205 brain edema 10.5 MMP9 IL2 IFNG CRP
206 cerebral aneurysms 10.5 MMP2 CTSB CCL2
207 relapsing polychondritis 10.5 IL2 IFNG CRP CCL2
208 stomatitis 10.5 TLR4 IL2 IFNG CD40LG
209 acute salpingitis 10.5
210 cat-scratch disease 10.5 HSPD1 CRP CD40LG
211 parenchymatous neurosyphilis 10.5 TLR6 TLR1
212 bartonellosis 10.5 HSPD1 CRP CD40LG
213 pulmonary sarcoidosis 10.5 IL2 IFNG CCL2
214 skeletal tuberculosis 10.5 IFNG CRP
215 cervical adenitis 10.5 HSPD1 CRP CD40LG
216 churg-strauss syndrome 10.5 MPO IL2 CD40LG
217 idiopathic interstitial pneumonia 10.5 IL13 IFNG CCL2
218 food allergy 10.5 TLR4 TLR2 IL13 IFNG
219 retinal vein occlusion 10.5 CXCL12 CD40LG CCL2
220 lymphadenitis 10.5 TLR4 IFNG CRP
221 rubella 10.5 TLR4 IL2 IFNG CD40LG
222 parotitis 10.5 MMP9 MMP2 CRP CD40LG
223 oral submucous fibrosis 10.5 MMP9 MMP2 CDH1
224 ureteral disease 10.5 LCN2 CDH1 CCL2
225 multiple cranial nerve palsy 10.4 MPO CRP
226 dengue hemorrhagic fever 10.4 IL13 IFNG CD40LG
227 stomach disease 10.4 TLR4 CRP CDH1
228 relapsing fever 10.4 HSPD1 CRP CD40LG
229 coronary stenosis 10.4 TLR4 CXCL12 CRP
230 light chain deposition disease 10.4 MMP9 MMP2
231 leukocyte disease 10.4 IL2 IL13 CRP CD40LG
232 carotid stenosis 10.4 MPO MMP9 CRP
233 perinatal necrotizing enterocolitis 10.4 TLR6 TLR4 TLR2 TLR1 CRP
234 blood coagulation disease 10.4 IL2 CRP CD40LG
235 juvenile rheumatoid arthritis 10.4 IL2 IFNG CRP CCL2
236 allergic asthma 10.4 TLR4 TLR2 IL13 IFNG
237 bronchopneumonia 10.4 TLR4 MPO CRP CD40LG
238 superficial basal cell carcinoma 10.4 TLR6 TLR4 TLR2 TLR1 IL2
239 dermatitis 10.4 IL2 IL13 IFNG CHI3L1
240 chronic fatigue syndrome 10.4 TLR4 IL2 IL13 IFNG
241 leukemia, acute monocytic 10.4 TLR4 TLR2 MPO CCL2
242 aortic aneurysm, familial abdominal, 1 10.4 MMP9 MMP2 CRP CCL2
243 mumps 10.4 IL2 IFNG CD40LG
244 acute proliferative glomerulonephritis 10.4 MPO CRP CD40LG CCL2
245 autoimmune disease of blood 10.4 MPO IL2 CRP CD40LG
246 oral cancer 10.4 MMP9 MMP2 CDH1
247 central nervous system vasculitis 10.4 MPO IFNG CRP CD40LG
248 invasive aspergillosis 10.4 TLR6 TLR4 TLR2 TLR1 IFNG
249 diphtheria 10.4 IL2 IL13 IFNG CD40LG
250 aspergillosis 10.4 TLR6 TLR4 TLR2 TLR1 IFNG
251 systemic scleroderma 10.4 IL13 IFNG CRP CD40LG
252 mouth disease 10.4 TLR4 IL13 IFNG CRP
253 pericardium disease 10.4 MPO IFNG CRP CD40LG
254 toxoplasmosis 10.4 TLR4 TLR2 TLR1 IFNG CD40LG
255 crescentic glomerulonephritis 10.4 MPO LCN2 CCL2
256 pulmonary emphysema 10.4 MMP9 MMP2 IFNG
257 pyosalpinx 10.4
258 urinary tract obstruction 10.4 LCN2 CRP CDH1 CCL2
259 hemorrhagic disease 10.4 MPO CRP CD40LG
260 chickenpox 10.4 TLR2 IL2 IFNG CRP CD40LG
261 myd88 deficiency 10.4 TLR6 TLR4 TLR2 TLR1 TIRAP
262 irak4 deficiency 10.4 TLR6 TLR4 TLR2 TLR1 TIRAP
263 sclerosing cholangitis 10.4 TLR4 MPO IL2 CD40LG
264 lichen planus 10.4 TLR2 IL2 IFNG
265 hypersensitivity reaction type iv disease 10.4 TLR2 IL2 IFNG CRP CD40LG
266 microvascular complications of diabetes 1 10.4 MMP9 CXCL12 CCL2
267 herpes zoster 10.4 TLR2 IL2 IFNG CRP CD40LG
268 paracoccidioidomycosis 10.4 TLR4 TLR2 IL2 IFNG CD40LG
269 gastric cardia carcinoma 10.4 CTSB CDH1
270 mycoplasma pneumoniae pneumonia 10.4 TLR2 IL13 IFNG CRP CD40LG
271 parasitic helminthiasis infectious disease 10.4 TLR4 TLR2 IL2 IL13 CD40LG
272 pyelitis 10.4 TLR4 TLR2 LCN2 CRP CD40LG
273 tularemia 10.4 TLR4 TLR2 HSPD1 CD40LG
274 oral cavity cancer 10.4 TLR6 TLR2 MPO CD40LG
275 autoimmune disease of gastrointestinal tract 10.4 TLR4 IL2 IFNG CRP CD40LG
276 contact dermatitis 10.4 TLR4 TLR2 IL2 IFNG CCL2
277 mixed connective tissue disease 10.4 IFNG HSPD1 CD40LG
278 measles 10.4 TLR4 TLR2 IL2 IFNG CD40LG
279 preterm premature rupture of the membranes 10.4 TLR4 TLR2 MMP9 MMP2 CRP
280 legionellosis 10.4 TLR4 TLR2 HSPD1 CD40LG
281 nasal cavity disease 10.4 TLR4 TLR2 IL2 IL13 IFNG
282 limb ischemia 10.4 MMP9 MMP2 CXCL12 CCL2
283 glomerulonephritis 10.4 MPO LCN2 CD40LG CCL2
284 monocytic leukemia 10.4 TLR4 MPO IFNG CCL2
285 renal fibrosis 10.4 MMP9 MMP2 CDH1 CCL2
286 opportunistic bacterial infectious disease 10.4 IFNG HSPD1 CRP CD40LG
287 acute female pelvic peritonitis 10.4
288 cerebrovascular disease 10.4 TLR4 MMP9 CRP CHI3L1 CD40LG
289 uveal disease 10.4 IL2 IFNG CRP CD40LG CCL2
290 osteomyelitis 10.4 TLR4 TLR2 IL13 IFNG CCL2
291 severe acute respiratory syndrome 10.4 IL2 IFNG CRP CD40LG CCL2
292 combined t cell and b cell immunodeficiency 10.4 IL2 IFNG CXCL12 CD40LG
293 middle ear disease 10.4 TLR4 TLR2 MPO CRP CD40LG
294 demyelinating disease 10.4 MMP9 IL2 IFNG CD40LG CCL2
295 lepromatous leprosy 10.3 TLR2 IL2 IFNG HSPD1
296 spondyloarthropathy 1 10.3 TLR4 HSPD1 CRP CD40LG
297 cellulitis 10.3 IL2 IFNG CRP CHI3L1 CD40LG
298 septic arthritis 10.3 TLR4 TLR2 MMP2 IFNG CRP
299 tetanus 10.3 IL2 IL13 IFNG CRP CD40LG
300 antiphospholipid syndrome 10.3 TLR4 CRP CD40LG
301 granulomatosis with polyangiitis 10.3 TLR4 TLR2 MPO CRP CD40LG
302 streptococcus pneumonia 10.3 TLR6 TLR4 TLR2 TLR1 CRP CD40LG
303 takayasu arteritis 10.3 MMP9 MMP2 IL2 CRP CD40LG
304 acute pancreatitis 10.3 TLR4 MPO CTSB CRP
305 varicose veins 10.3 MMP9 MMP2 CCL2
306 vaginal disease 10.3 TLR6 TLR4 TLR2 TLR1 IL2 CRP
307 schistosomiasis 10.3 IL2 IL13 IFNG CD40LG CCL2
308 lymphoid interstitial pneumonia 10.3 IL2 CRP CD40LG
309 cholangitis 10.3 TLR4 MPO IL2 CRP CD40LG
310 essential thrombocythemia 10.3 MPO LCN2 CRP CD40LG
311 scleral disease 10.3 MPO IL2 IFNG CRP CD40LG
312 bacterial meningitis 10.3 TLR4 TLR2 MMP9 IFNG CRP CCL2
313 q fever 10.3 TLR4 TLR2 TLR1 IFNG CD40LG CCL2
314 extrinsic cardiomyopathy 10.3 TLR4 TLR2 IL2 CRP CD40LG CCL2
315 splenic disease 10.3 TLR4 TLR2 IL2 IFNG CRP CD40LG
316 temporal arteritis 10.3 MPO IFNG CRP CD40LG CCL2
317 conjunctival disease 10.3 TLR4 TLR2 IL2 IL13 CRP CD40LG
318 endocardium disease 10.3 TLR4 TLR2 HSPD1 CRP CD40LG
319 paranasal sinus disease 10.3 MPO IL13 IFNG CRP CD40LG
320 viral hepatitis 10.3 TLR4 TLR2 IL2 IFNG CRP CD40LG
321 lymphoma, mucosa-associated lymphoid type 10.3 TLR4 TLR2 TLR1 HSPD1 CD40LG
322 epidemic typhus 10.3 TLR4 TLR2 HSPD1 CRP CD40LG
323 uveitis 10.3 IL2 IFNG HSPD1 CCL2
324 upper respiratory tract disease 10.3 TLR4 TLR2 IL2 IL13 CRP CD40LG
325 pulmonary tuberculosis 10.3 TLR4 TLR2 IL2 IFNG CRP CCL2
326 visceral leishmaniasis 10.3 TLR4 TLR2 IL2 IL13 IFNG CRP
327 crohn's disease 10.3 TLR4 TLR2 IL2 IFNG CRP CCL2
328 trypanosomiasis 10.3 TLR6 TLR4 TLR2 IL2 IFNG CCL2
329 chagas disease 10.3 TLR6 TLR4 TLR2 IL2 IFNG CCL2
330 relapsing-remitting multiple sclerosis 10.3 TLR4 MMP9 IL2 IFNG CD40LG CCL2
331 respiratory failure 10.3 TLR4 MPO IL13 CRP CD40LG
332 scrub typhus 10.3 TLR4 TLR2 LCN2 IFNG CRP CD40LG
333 severe combined immunodeficiency 10.3
334 endocarditis 10.3 TLR6 TLR2 IFNG HSPD1 CRP
335 cutaneous leishmaniasis 10.3 TLR4 TLR2 IL2 IL13 IFNG CCL2
336 pulmonary fibrosis 10.3 MPO MMP9 MMP2 IL13 CCL2
337 autosomal dominant polycystic kidney disease 10.2 LCN2 CXCL12 CDH1 CCL2
338 retinal detachment 10.2 MMP9 MMP2 IFNG CXCL12 CCL2
339 gliosarcoma 10.2 MMP9 MMP2 IL2 IFNG CTSB
340 pre-eclampsia 10.2 TLR4 MMP9 MMP2 CRP CD40LG
341 tonsillitis 10.2 TLR4 TLR2 TLR1 MPO IL2 IFNG
342 dermatitis, atopic 10.2 TLR4 TLR2 IL2 IL13 IFNG CCL2
343 rectal disease 10.2 TLR6 TLR4 TLR2 TLR1 IL2 CRP
344 macular degeneration, age-related, 1 10.2 TLR4 TLR2 MMP9 MMP2 CRP CCL2
345 trichomoniasis 10.2
346 chronic pain 10.2
347 agammaglobulinemia 10.2
348 gingivitis 10.2 TLR2 MPO MMP9 IL2 IFNG CCL2
349 filariasis 10.2 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
350 herpangina 10.2 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
351 colitis 10.2 TLR4 TLR2 MPO IL2 IL13 IFNG
352 plasmodium falciparum malaria 10.2 IFNG CRP CD40LG
353 ovarian cyst 10.2
354 bacteriuria 10.2 TLR4 TLR2 TLR1 TIRAP CRP CD40LG
355 mycobacterium tuberculosis 1 10.2 TLR4 TLR2 TLR1 IFNG HSPD1 CRP
356 nose disease 10.2 TLR4 TLR2 IL2 IL13 IFNG CRP
357 ulcerative colitis 10.2 TLR4 MPO IL2 IL13 IFNG CRP
358 psoriatic arthritis 10.2 TLR4 TLR2 IL2 IL13 IFNG CRP
359 primary systemic mycosis 10.2 TLR2 IL2 IFNG HSPD1 CRP CD40LG
360 kawasaki disease 10.2 MMP9 IL2 HSPD1 CRP CD40LG CCL2
361 chronic kidney disease 10.2 TLR4 MPO MMP9 LCN2 CRP CCL2
362 leishmaniasis 10.2 TLR4 TLR2 IL2 IL13 IFNG CRP
363 leukorrhea 10.2
364 autoimmune disease of central nervous system 10.1 TLR4 TLR2 IL2 IL13 IFNG CD40LG
365 bronchitis 10.1 TLR4 TLR2 MPO MMP9 IL13 CRP
366 gingival overgrowth 10.1 MMP2 IL2 CTSB
367 osteoporosis 10.1 TLR4 MMP9 IL2 IFNG CRP CD40LG
368 bronchiolitis obliterans 10.1 TLR4 TLR2 MPO MMP9 IL13 IFNG
369 actinomycosis 10.1
370 ovarian epithelial cancer 10.1
371 pulmonary disease, chronic obstructive 10.1 TLR4 TLR2 MPO MMP9 IL13 CRP
372 pleurisy 10.1 TLR4 TLR2 MPO IL2 IFNG CRP
373 sarcoidosis 1 10.1 IL2 IL13 IFNG CRP CHI3L1 CD40LG
374 lyme disease 10.1 TLR6 TLR2 TLR1 MMP9 HSPD1 CRP
375 interstitial lung disease 10.1 MMP9 IL13 IFNG CXCL12 CRP CD40LG
376 coccidiosis 10.1 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
377 primary biliary cirrhosis 10.1 TLR4 IL2 IFNG HSPD1 CD40LG CCL2
378 reactive arthritis 10.1 TLR4 TLR2 MPO IFNG HSPD1 CRP
379 myelodysplastic syndrome 10.1 TLR2 MPO MMP9 IL2 IFNG CXCL12
380 gastric adenocarcinoma 10.1 MMP9 MMP2 IFNG CXCL12 CRP CDH1
381 atherosclerosis susceptibility 10.1 TLR4 MPO MMP9 HSPD1 CRP CCL2
382 peripheral nervous system disease 10.1 TLR4 TLR2 TLR1 IL2 IFNG CRP
383 testicular disease 10.1 TLR4 TLR2 TLR1 IL2 IFNG HSPD1
384 parametritis 10.1
385 vaginitis 10.1
386 vulvovaginitis 10.1
387 47,xyy 10.1
388 chediak-higashi syndrome 10.1
389 hypoglycemia 10.1
390 lymph node disease 10.1 TLR4 TLR2 IL2 IFNG HSPD1 CRP
391 viral infectious disease 10.1 TLR4 TLR2 TLR1 IL2 IL13 IFNG
392 leptospirosis 10.0 TLR2 TLR1 LCN2 IL2 IFNG CRP
393 vasculitis 10.0 MPO LCN2 HSPD1 CRP CD40LG CCL2
394 arthritis 10.0 TLR4 TLR2 MMP9 IL13 IFNG CXCL12
395 renal cell carcinoma, nonpapillary 10.0 MMP9 MMP2 IL2 IL13 IFNG CDH1
396 leukemia, acute myeloid 10.0 MPO MMP9 IL2 IFNG CXCL12 CDH1
397 myelofibrosis 10.0 MPO CXCL12 CRP CD40LG
398 herpes simplex 10.0
399 intracranial aneurysm 10.0 TLR4 MMP2 CCL2
400 arteriosclerosis 10.0 TLR4 MMP9 IFNG HSPD1 CXCL12 CRP
401 heart disease 10.0 TLR4 MMP9 LCN2 CXCL12 CRP CD40LG
402 autoimmune disease of musculoskeletal system 10.0 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
403 opportunistic mycosis 10.0 TLR6 TLR4 TLR2 TLR1 IL2 IL13
404 fungal infectious disease 10.0 TLR6 TLR4 TLR2 TLR1 IL2 IL13
405 commensal bacterial infectious disease 10.0 TLR4 TLR2 TLR1 IL2 IFNG HSPD1
406 bronchiolitis 10.0 TLR6 TLR4 TLR2 TLR1 IL13 IFNG
407 celiac disease 1 10.0 TLR6 TLR4 TLR2 TLR1 IL2 IL13
408 integumentary system disease 10.0 TLR4 TLR2 TLR1 IL2 IL13 IFNG
409 leprosy 3 10.0 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
410 periodontitis 10.0 TLR4 TLR2 MPO MMP9 MMP2 IFNG
411 intracranial berry aneurysm 9.9 TLR4 MMP9 CRP
412 pancreatic adenocarcinoma 9.9 MMP9 MMP2 IL2 CXCL12 CDH1
413 thrombocytopenia 9.9 TLR4 TLR2 MMP9 IL2 IFNG CXCL12
414 endometrial cancer 9.9
415 human immunodeficiency virus type 1 9.9
416 tuberculous salpingitis 9.9
417 acute gonococcal cervicitis 9.9
418 leiomyoma 9.9
419 chronic gonococcal salpingitis 9.9
420 fallopian tube carcinoma 9.9
421 thrombophlebitis 9.9
422 myofibroma 9.9
423 ureteral obstruction 9.9
424 acute endometritis 9.9
425 genital herpes 9.9
426 cervix uteri carcinoma in situ 9.9
427 cervical intraepithelial neoplasia 9.9
428 haemophilus influenzae 9.9
429 back pain 9.9
430 leukocyte adhesion deficiency, type i 9.9
431 leukemia, chronic lymphocytic 9.9
432 digeorge syndrome 9.9
433 anemia, autoimmune hemolytic 9.9
434 ataxia-telangiectasia 9.9
435 methane production 9.9
436 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.9
437 ataxia and polyneuropathy, adult-onset 9.9
438 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative 9.9
439 autoimmune lymphoproliferative syndrome 9.9
440 omenn syndrome 9.9
441 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive 9.9
442 immunodeficiency 25 9.9
443 alacrima, achalasia, and mental retardation syndrome 9.9
444 global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies 9.9
445 hemophagocytic lymphohistiocytosis 9.9
446 immunoglobulin alpha deficiency 9.9
447 scoliosis 9.9
448 lymphoproliferative syndrome 9.9
449 dysgammaglobulinemia 9.9
450 telangiectasis 9.9
451 guillain-barre syndrome 9.9
452 polyneuropathy 9.9
453 thrombocytopenia due to platelet alloimmunization 9.9
454 neuroendocrine tumor 9.9
455 ectodermal dysplasia 9.9
456 pustulosis of palm and sole 9.9
457 poliomyelitis 9.9
458 chronic inflammatory demyelinating polyradiculoneuropathy 9.9
459 demyelinating polyneuropathy 9.9
460 chronic salpingitis 9.9
461 adenosine deaminase deficiency 9.9
462 hemolytic anemia 9.9
463 paraplegia 9.9
464 lymphopenia 9.9
465 psoriasis 9.9
466 albinism 9.9
467 atypical mycobacteriosis, familial 9.9
468 glioma 9.9
469 multifocal motor neuropathy 9.9
470 spinal cord injury 9.9
471 glial tumor 9.9
472 esophageal cancer 9.9 TLR4 MMP9 MMP2 IL2 IFNG CXCL12
473 diabetes mellitus, noninsulin-dependent 9.9 TLR6 TLR4 TLR2 TLR1 MMP9 LCN2
474 glioblastoma multiforme 9.8 MMP9 MMP2 IL2 IL13 IFNG CXCL12
475 parasitic protozoa infectious disease 9.8 TLR6 TLR4 TLR2 TLR1 IL2 IL13
476 bronchial disease 9.8 TLR6 TLR4 TLR2 TLR1 IL2 IL13
477 otitis media 9.8 TLR4 TLR2 TLR1 MPO IL2 IL13
478 meralgia paraesthetica, familial 9.8
479 pelvic organ prolapse 9.8
480 ureterocele 9.8
481 renal hypodysplasia/aplasia 1 9.8
482 uterus bicornis bicollis with partial vaginal septum and unilateral hematocolpos with ipsilateral renal agenesis 9.8
483 lipoid congenital adrenal hyperplasia 9.8
484 insulin-like growth factor i 9.8
485 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 9.8
486 body mass index quantitative trait locus 9 9.8
487 body mass index quantitative trait locus 8 9.8
488 body mass index quantitative trait locus 4 9.8
489 body mass index quantitative trait locus 10 9.8
490 body mass index quantitative trait locus 7 9.8
491 diabetes mellitus, ketosis-prone 9.8
492 major affective disorder 8 9.8
493 body mass index quantitative trait locus 12 9.8
494 major affective disorder 9 9.8
495 body mass index quantitative trait locus 14 9.8
496 body mass index quantitative trait locus 18 9.8
497 body mass index quantitative trait locus 19 9.8
498 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.8
499 body mass index quantitative trait locus 20 9.8
500 small cell carcinoma 9.8
501 thrombosis 9.8
502 paragonimiasis 9.8
503 strongyloidiasis 9.8
504 salpingo-oophoritis 9.8
505 hydronephrosis 9.8
506 endometriosis of ovary 9.8
507 portal vein thrombosis 9.8
508 chancroid 9.8
509 inclusion conjunctivitis 9.8
510 interstitial cystitis 9.8
511 mental depression 9.8
512 heart septal defect 9.8
513 histoplasmosis 9.8
514 atrial heart septal defect 9.8
515 hepatitis b 9.8
516 constipation 9.8
517 pharyngitis 9.8
518 myoma 9.8
519 chronic granulomatous disease 9.8
520 bipolar disorder 9.8
521 sleep disorder 9.8
522 lice infestation 9.8
523 adenoma 9.8
524 diverticulitis 9.8
525 peptic ulcer disease 9.8
526 peptic ulcer perforation 9.8
527 scabies 9.8
528 intestinal obstruction 9.8
529 paralytic ileus 9.8
530 in situ carcinoma 9.8
531 uterine inversion 9.8
532 cytokine deficiency 9.8
533 double uterus-hemivagina-renal agenesis 9.8
534 infectious myocarditis 9.8
535 ovarian remnant syndrome 9.8
536 splenomegaly 9.8
537 streptococcal group a invasive disease 9.8
538 depression 9.8
539 longitudinal vaginal septum 9.8
540 transient pseudohypoaldosteronism 9.8
541 streptococcal toxic-shock syndrome 9.8
542 precursor t-cell acute lymphoblastic leukemia 9.8
543 bone inflammation disease 9.8 TLR6 TLR4 TLR2 TLR1 MMP9 IL2
544 myeloma, multiple 9.7 TLR4 MMP9 MMP2 IL2 IFNG CXCL12
545 neuroblastoma 9.7 MMP9 MMP2 IL2 IFNG CXCL12 CDH1
546 multiple sclerosis 9.6 TLR4 TLR2 MMP9 IL2 IL13 IFNG
547 eye disease 9.6 TLR4 TLR2 MMP9 MMP2 IL2 IL13
548 dilated cardiomyopathy 9.6 TLR4 MMP9 MMP2 IL2 IL13 IFNG
549 primary bacterial infectious disease 9.6 TLR6 TLR4 TLR2 TLR1 IL2 IL13
550 diabetes mellitus, type i 9.6 TLR6 TLR4 TLR2 TLR1 IL2 IL13
551 vascular disease 9.6 TLR4 MPO MMP9 IL2 IFNG HSPD1
552 pulmonary fibrosis, idiopathic 9.6 TLR4 TLR2 MMP9 MMP2 IL13 IFNG
553 behcet syndrome 9.4 TLR6 TLR4 TLR2 TLR1 MPO IL2
554 hypertension, essential 9.4 TLR6 TLR4 TLR2 TLR1 MPO MMP9
555 diabetes mellitus 9.3 TLR4 TLR2 MPO MMP9 MMP2 LCN2
556 asthma 9.2 TLR6 TLR4 TLR2 TLR1 MPO MMP9
557 systemic lupus erythematosus 9.0 TLR4 TLR2 MPO MMP9 MMP2 LCN2
558 rheumatoid arthritis 8.9 TLR4 TLR2 MPO MMP9 MMP2 IL2
559 malaria 8.9 TLR6 TLR4 TLR2 TLR1 TIRAP MPO
560 inflammatory bowel disease 8.6 TLR6 TLR4 TLR2 TLR1 MPO MMP9

Comorbidity relations with Pelvic Inflammatory Disease via Phenotypic Disease Network (PDN): (showing 1, show less)


Acute Cystitis

Graphical network of the top 20 diseases related to Pelvic Inflammatory Disease:



Diseases related to Pelvic Inflammatory Disease
Sources

Symptoms & Phenotypes for Pelvic Inflammatory Disease

About this section

UMLS symptoms related to Pelvic Inflammatory Disease:


fever, pruritus, pelvic pain

MGI Mouse Phenotypes related to Pelvic Inflammatory Disease:

45 (showing 11, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.35 CCL2 CD40LG CDH1 CHI3L1 CRP CTSB
2 cardiovascular system MP:0005385 10.34 CD40LG CDH1 CRP CXCL12 HSPD1 IFNG
3 hematopoietic system MP:0005397 10.34 CD40LG CHI3L1 CXCL12 HSPD1 IFNG IL13
4 cellular MP:0005384 10.29 CD40LG CDH1 CHI3L1 CTSB CXCL12 HSPD1
5 homeostasis/metabolism MP:0005376 10.25 CD40LG CDH1 CRP CTSB IFNG IL13
6 mortality/aging MP:0010768 10.2 CD40LG CDH1 CTSB CXCL12 HSPD1 IFNG
7 digestive/alimentary MP:0005381 10.06 CDH1 CTSB IFNG IL13 IL2 MMP9
8 muscle MP:0005369 9.91 CXCL12 HSPD1 IFNG IL13 MMP2 MMP9
9 neoplasm MP:0002006 9.76 CDH1 CTSB IFNG IL2 MMP2 MMP9
10 reproductive system MP:0005389 9.7 CD40LG CDH1 CXCL12 HSPD1 IFNG IL13
11 respiratory system MP:0005388 9.23 HSPD1 IFNG IL13 IL2 MMP2 MMP9
Sources

Drugs & Therapeutics for Pelvic Inflammatory Disease

About this section

Drugs for Pelvic Inflammatory Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 84, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
2
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
3
Azithromycin Approved Phase 4 83905-01-5 447043 55185
4
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
5
Gemifloxacin Approved, Investigational Phase 4 175463-14-6 5464436 9571107
6
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
7
Ofloxacin Approved Phase 4 82419-36-1 4583
8
Metronidazole Approved Phase 4 443-48-1 4173
9
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
10 Cytochrome P-450 Enzyme Inhibitors Phase 4
11 Norgestimate, ethinyl estradiol drug combination Phase 4
12 Antitubercular Agents Phase 4
13 Alkylating Agents Phase 4
14 Gentamicins Phase 4
15 Acidophilus Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Anti-Infective Agents Phase 4
19 Anti-Bacterial Agents Phase 4
20 Antiprotozoal Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Antimalarials Phase 4
23 Carboxymethylcellulose Sodium Phase 4
24
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
25
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
26
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
27
Polyestradiol phosphate Approved Phase 3 28014-46-2
28
Ceftriaxone Approved Phase 3 73384-59-5 5361919 5479530
29
Copper Approved, Investigational Phase 3 7440-50-8 27099
30
Cefixime Approved, Investigational Phase 3 79350-37-1 5362065 54362
31 Estradiol 17 beta-cypionate Phase 3
32 Contraceptives, Oral Phase 3
33 Estradiol 3-benzoate Phase 3
34 Contraceptives, Oral, Combined Phase 3
35 Contraceptive Agents Phase 3
36 Copper Supplement Phase 3
37 Hormones Phase 3
38
Clavulanate Approved, Vet_approved Phase 2 58001-44-8 5280980
39
Ticarcillin Approved, Investigational, Vet_approved Phase 2 34787-01-4 36921
40
Ertapenem Approved, Investigational Phase 2 153832-46-3 150610
41
Furosemide Approved, Vet_approved Phase 2 54-31-9 3440
42 Kava Approved, Investigational, Nutraceutical Phase 2 9000-38-8
43 beta-Lactamase Inhibitors Phase 2
44 diuretics Phase 2
45 Pharmaceutical Solutions Phase 1
46
Curcumin Approved, Experimental, Investigational 458-37-7 969516
47
Menotropins Approved 61489-71-2, 9002-68-0 5360545
48
Telithromycin Approved 191114-48-4 70789201 5462516
49
Clarithromycin Approved 81103-11-9 84029
50
Amoxicillin Approved, Vet_approved 26787-78-0 33613
51
Cefuroxime Approved 55268-75-2 5479529 5361202
52
Levonorgestrel Approved, Investigational 797-63-7, 17489-40-6 13109
53
Lidocaine Approved, Vet_approved 137-58-6 3676
54
Iron Approved, Experimental 15438-31-0, 7439-89-6 27284 23925
55
Aspartic acid Approved, Nutraceutical 56-84-8 5960
56 Analgesics, Non-Narcotic
57 Antirheumatic Agents
58 Anti-Inflammatory Agents, Non-Steroidal
59 Chorionic Gonadotropin
60 Gonadotropins, Pituitary
61 Triptorelin Pamoate
62 cefuroxime axetil
63 Liver Extracts
64 Fluoroquinolones
65 Amoxicillin-Potassium Clavulanate Combination
66 Cytochrome P-450 CYP3A Inhibitors
67 N-Methylaspartate
68 Anti-Retroviral Agents
69 Complement System Proteins
70 Analgesics
71 Trace Elements
72 Nutrients
73 Micronutrients
74 Sodium Channel Blockers
75 Anti-Arrhythmia Agents
76 Anesthetics, Local
77 Diuretics, Potassium Sparing
78 Antioxidants
79 Vitamins
80 Protective Agents
81 Omega 3 Fatty Acid
82 Anesthetics
83 Vaccines
84
L-Alanine Nutraceutical 56-41-7 5950

Interventional clinical trials:

(showing 76, show less)
# Name Status NCT ID Phase Drugs
1 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
2 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Unknown status NCT03380793 Phase 4 morinidazole
3 Randomized, Open-label, Multicenter Study of Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection Unknown status NCT03532464 Phase 4 azithromycin;doxycycline
4 Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials Completed NCT01799356 Phase 4 Moxifloxacin;Ofloxacin;Metronidazole
5 Phase 4 Study of Azitromicin in the Treatment of PID Completed NCT01241110 Phase 4 Ofloxacin group A, Azitromycin group B;azitromycin
6 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
7 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
8 Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea Completed NCT00926796 Phase 4 Azithromycin;Gentamicin;Gemifloxacin
9 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
10 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
11 A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome)：a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study Not yet recruiting NCT04031664 Phase 4 Qianjin Capsule of Gynaecology
12 A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation):a Randomized, Double Blind, Parallel Control of Positive Drugs,Multi-center Clinical Study Not yet recruiting NCT04035785 Phase 4 Kangfu Anti-inflammatory Suppository
13 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
14 Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic Inflammatory Disease (PID) Completed NCT00683865 Phase 3 Ofloxacin;Avelox (Moxifloxacin, BAY12-8039)
15 A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 Days in Subjects With an Uncomplicated Pelvic Inflammatory Disease (PID). Moxifloxacin, Metronidazole, and Levofloxacin in Asia (MONALISA Study) Completed NCT00453349 Phase 3 Moxifloxacin (Avelox, BAY12-8039);Levofloxacin & Metronidazole
16 A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Pelvic Inflammatory Disease (PID) Requiring Initial Intravenous Therapy Completed NCT00871494 Phase 3 Azithromycin
17 Home Screening for Chlamydia Surveillance Completed NCT00177437 Phase 3
18 A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone Completed NCT01473836 Phase 3 Metronidazole;Ceftriaxone sodium
19 A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCeptâ„¢, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability Active, not recruiting NCT03633799 Phase 3 VeraCept
20 A Randomized Trial to Evaluate the Need for Empiric Therapy for Mucopurulent Cervicitis of Unknown Etiology Terminated NCT01072136 Phase 3 Azithromycin;Cefixime
21 Clinical Promotion Research of Complex Treatment With TCM to Diagnosis and Treatment on Different Syndrome Types of Pelvic Inflammatory Disease Sequelae Unknown status NCT02972151 Phase 2 Comprehensive treatment of TCM
22 The Clinical Effect of Fuke Qianjin Capsule on Chronic Pelvic Pain Caused by Pelvic Inflammation Unknown status NCT03251560 Phase 2 Fuke Qianjin capsule;Placebo oral capsule
23 The Importance of Anti-anaerobic Therapy for Acute PID Completed NCT01160640 Phase 2 Ceftriaxone;Doxycycline;Metronidazole;Placebo Oral Capsule
24 A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients Completed NCT00092170 Phase 2 MK0826, ertapenem sodium;Comparator: Ticarcillin/Clavulanate
25 MANAGEMENT OF THE PATIENT WITH ACUTE ABDOMEN SUBMITTED TO URGENT ABDOMINAL SURGERY: a Pilot Randomized Multicentre Study Completed NCT01911702 Phase 2
26 Intrauterine Infusion of Autologous Platelet-Rich Plasma (PRP) in Women With Thin Endometrium Undergoing Embryo-transfer. Recruiting NCT03067623 Phase 2 PRP
27 Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of Increasing Single Oral Doses of BAY1834845 Including Relative Bioavailability of a Liquid Versus a Solid Dosage in Healthy Male Volunteers Completed NCT03054402 Phase 1 BAY1834845;Placebo
28 Curcumin Supplementation for Gynecological Diseases Including Pelvic Inflammatory Disease Endometritis, Endometriosis: A Pilot Study Unknown status NCT03016039
29 Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users Unknown status NCT03261804
30 Rate of Pelvic Inflammatory Disease and Tubo-ovarian Abscess at SMH Completed NCT00783419
31 Improving Primary Care Follow-up for Adolescents With PID: A Randomized Controlled Trial Using Text Message Reminders Completed NCT01299259
32 To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy Completed NCT01842100 Universal antibiotic prophylaxis
33 Characterization of Novel Organisms in the Genital Tract of Women With PID and Determination of Their Association With Endometritis. Completed NCT01236131
34 Immunopathogenesis of Chlamydia Trachomatis Infection Completed NCT00607659
35 Drug Use Investigation Of Azithromycin Iv Completed NCT01671280 Azithromycin IV
36 Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease Completed NCT00115388
37 Technology Enhanced Community Health Nursing (TECH-N) to Prevent Recurrent Sexually Transmitted Infections After Pelvic Inflammatory Disease Completed NCT01640379
38 Randomized Trial of Laparoscopic Versus Abdominal Hysterectomy for Benign Indications and Impact on Surgical Success Completed NCT01793584
39 Recurrent Bacterial Vaginosis (RBV): Efficiency of Metronidazole in Comparison to Metronidazole and Intravaginal Acidifying Gel: A Randomized Investigator-blinded Controlled Trial Completed NCT00545181 Vaginal acidifying gel (RepHresh);Metronidazole control
40 Zithromac Iv Special Investigation For Legionella Infection. Completed NCT01784770 Azithromycin IV
41 Longitudinal Study of Vaginal Flora Completed NCT00340275
42 DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women Completed NCT01874158
43 The Measurement of Endometrial Volume and Sub-endometrial Vascularity to Replace the Traditional Endometrial Thickness as Predictors of In-vitro Fertilization Success Completed NCT02381821 GnRH agonist
44 Antigen-specific Cell Mediated Immune Response to Chlamydia Trachomatis Completed NCT00970749
45 Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population Completed NCT01434173 Moxifloxacin (Avelox, BAY12-8039);Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
46 Quick Start Insertion of Mirena and ParaGard Intrauterine Contraceptive Devices Completed NCT01730911
47 MOCHI: A Randomized Controlled Trial of Mindfulness as a Treatment for Chronic Pelvic Pain in Active Duty Women Completed NCT04104542
48 Evaluation of an Inpatient Sexual Risk Behavior Assessment Program Completed NCT03502226
49 HIV Risk Reduction for Women Reporting Intimate Partner Violence Completed NCT01695694
50 Comparison of Two IUDs Among Cape Town HIV-positive Women: A Randomized Controlled Trial Assessing Safety of Registered Products in South Africa Completed NCT01721798
51 Home Sampling Versus Conventional Sampling for Screening of Urogenital Chlamydia Trachomatis in Young Men and Women. - A Randomised Control Trial Completed NCT00283127
52 Complement Diagnosis of Acute Appendicitis Completed NCT03450642
53 Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract Completed NCT00299663
54 Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women Completed NCT02272231
55 The Effect of the Levonorgestrel-Releasing Intrauterine System and the Copper-Intrauterine Device (TCu 380A) on Subendometrial Microvascularization and Uterine Artery Blood Flow. Completed NCT00489463
56 Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase of Infertile Women With Natural Cycles Completed NCT01533350
57 Diagnostic Yield of Narrow Band Imaging (NBI) and Standard Visible White Light Laparoscopy for the Detection of Endometriosis Completed NCT01464775
58 Prospective Data Collection of Patients With Pelvic Inflammatory Disease Recruiting NCT02567812
59 Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID Recruiting NCT03828994
60 Prevention of Diseases Induced by Chlamydia Trachomatis Recruiting NCT02904811
61 Efficacy of Resistive Capacitive Monopolar Radiofrequency in the Physiotherapeutic Treatment of Chronic Pelvic Pain: Randomized Clinical Trial. Recruiting NCT03797911
62 European Active Surveillance Study of LCS12 Recruiting NCT02146950
63 Chlamydia Tracomatis and Other Lower Genital Tract Infections Among Women With Unexplained Early Miscarriage Recruiting NCT04152278
64 Enriched Environments: a Multi-level Integrative Medicine Intervention for Endometriosis Recruiting NCT04179149
65 Analgesic Efficacy of Intrauterine Lidocaine Flushing in Hysterosalpingo-foam Sonography: A Double-blind Randomized Controlled Trial Recruiting NCT04433611 2% lidocaine;0.9 % normal saline
66 Darwish Test (Office Hysteroscopic Bubble Suction and Tubal Peristalsis) in Women Using Minipills Recruiting NCT04368104
67 Darwish Test (Office Hysteroscopic Bubble Suction and Tubal Peristalsis) in Cases of Intrauterine Polyp(s) Recruiting NCT04367415
68 Effect of an Anti-inflammatory Diet on the Nutritional Status and Cytokine Expression of Patients With Locally Advanced Cervical Cancer: A Randomized Clinical Trial Recruiting NCT03994055
69 Darwish Hysteroscopic Test (Hysteroscopic Bubble Suction and Tubal Peristalsis of Darwish Triad) in Myomatous Uterus Recruiting NCT04357054
70 Effect of Prophylactic Antibiotics for Hysterosalpingography on Post Procedure Morbidity Recruiting NCT04234945 Doxycycline Capsule;Multivitamins W/Iron Tab
71 STD Testing in Outpatient Practices-The STOP STDs Study Active, not recruiting NCT03246815
72 Cross Sectional Study of Iatrogenic Urinary Tract Injuries During Obstetric and Gynecological Operations in Assiut University Women Health Hospital Not yet recruiting NCT04162782
73 Comparative Study of Hysteroscopic Versus Laparoscopic Tubal Occlusion in Cases of Communicating Hydrosalpinx and Planning for IVF Not yet recruiting NCT04037813
74 Immunisation for Adolescents Against Serious Communicable Diseases Not yet recruiting NCT04398849
75 Improving the Detection of STIs in the Pediatric Emergency Department: A Pragmatic Trial Not yet recruiting NCT03715335
76 A Randomized, Controlled Trial of Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis Terminated NCT00997516

Search NIH Clinical Center for Pelvic Inflammatory Disease

Cochrane evidence based reviews: pelvic inflammatory disease

Sources

Genetic Tests for Pelvic Inflammatory Disease

About this section
Sources

Anatomical Context for Pelvic Inflammatory Disease

About this section

MalaCards organs/tissues related to Pelvic Inflammatory Disease:

40
Testes, Uterus, Ovary, Liver, Colon, Breast, T Cells
Sources

Publications for Pelvic Inflammatory Disease

About this section

Articles related to Pelvic Inflammatory Disease:

(showing 3931, show less)
# Title Authors PMID Year
1
Implementing Mycoplasma genitalium testing across a London-based sexual health service: A quality improvement project. 42
32036754 2020
2
Endometrial CD138 count appears to be a negative prognostic indicator for patients who have experienced previous embryo transfer failure. 42
31843086 2019
3
Antimicrobial resistance in bacteria isolated from the uteri of horses with endometriosis. 42
31732630 2019
4
Chlamydia pneumoniae as a respiratory pathogen. 54 61
11861211 2002
5
Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-shock protein in women with pelvic inflammatory disease. 61 54
9498452 1998
6
Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin. 54 61
18475331 1993
7
Differential human serologic response to two 60,000 molecular weight Chlamydia trachomatis antigens. 61 54
2205652 1990
8
Genotyping of Mycoplasma genitalium suggests de novo acquisition of antimicrobial resistance, Queensland, Australia. 61
32493781 2020
9
Structure and mechanism of the Nap adhesion complex from the human pathogen Mycoplasma genitalium. 61
32513917 2020
10
Fitz-Hugh-Curtis syndrome: A cause of right upper quadrant abdominal pain. 61
32145988 2020
11
Mycoplasma genitalium and Trichomonas vaginalis: addressing disparities and promoting public health control of two emerging sexually transmitted infections. 61
32520821 2020
12
Innate Lymphoid Cells Are Required for Endometrial Resistance to Chlamydia trachomatis Infection. 61
32341118 2020
13
The acceptability of using IUDs among Egyptian nulliparous women: a cross-sectional study. 61
32503576 2020
14
A population-specific optimized GeneXpert pooling algorithm for Chlamydia trachomatis and Neisseria gonorrhoeae to reduce cost of molecular STI screening in resource-limited settings. 61
32522828 2020
15
CLEARANCE OF MYCOPLASMA GENITALIUM AND TRICHOMONAS VAGINALIS AMONG ADOLESCENTS AND YOUNG ADULTS WITH PELVIC INFLAMMATORY DISEASE: RESULTS FROM THE TECH-N STUDY. 61
32569258 2020
16
"Effectiveness of Jinying capsule on pelvic inflammatory disease in patients with symptom pattern of damp and heat accumulation: a double-blinded, multicenter, randomized, placebo-controlled clinical trial". 61
32506857 2020
17
Pelvic inflammatory disease by Streptococcus constellatus. Clinical experience and a review 61
32515179 2020
18
Tubo-ovarian abscess in postmenopausal women: A systematic review. 61
32413520 2020
19
Maternal Health after Stillbirth: Postpartum Hospital Readmission in California. 61
32365389 2020
20
Granulomatous Peritonitis secondary to Chlamydia Trachomatis: A case report. 61
32195309 2020
21
Increased prevalence of endocervical Mycoplasma and Ureaplasma colonization in infertile women with tubal factor. 61
32031768 2020
22
Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial. 61
32442189 2020
23
Erratum to: Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease, Ectopic Pregnancy, and Female Infertility: A Retrospective Cohort Study Among Primary Care Patients. 61
31535123 2020
24
Ectopic Pregnancy: Diagnosis and Management. 61
32412215 2020
25
Ectopic Pregnancy: Diagnosis and Management. 61
32352259 2020
26
Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis. 61
32037193 2020
27
Anorectal malformation with didelphys uterus: Extremely rare anomaly and successful neoanal sphincter reconstruction with gracilis muscle flap. 61
32268658 2020
28
Pelvic Inflammatory Disease Due to Mycoplasma genitalium: A Character in Search of an Author. 61
32543648 2020
29
Blood Pressure Readings, Tonsillectomy in Children, Venous Ulcers, Opioids, Pelvic Inflammatory Disease. 61
32352726 2020
30
Presence and Concentrations of Select Bacterial Vaginosis-Associated Bacteria Are Associated With Increased Risk of Pelvic Inflammatory Disease. 61
32149953 2020
31
Inflammation calls for more: Severe pelvic inflammatory disease with or without endometriosis. Outcomes on 311 laparoscopically treated women. 61
32433940 2020
32
Concurrent Escherichia coli tubo-ovarian abscess and Campylobacter jejuni gastroenteritis: A case report. 61
32257830 2020
33
Septic shock following hysteroscopy - A case report. 61
32082994 2020
34
Unusual presentation of bilateral pyosalpinx mimicking an ovarian torsion: A case report. 61
32153774 2020
35
A profile of the cobas® TV/ MG test for the detection of Trichomonas vaginalis and Mycoplasma genitalium. 61
31917618 2020
36
High rates of